Compare PHIN & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | TMDX |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.4B |
| IPO Year | 2023 | 2019 |
| Metric | PHIN | TMDX |
|---|---|---|
| Price | $75.71 | $68.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | $70.00 | ★ $148.22 |
| AVG Volume (30 Days) | 466.4K | ★ 1.1M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 1.66% | N/A |
| EPS Growth | 84.09 | ★ 382.18 |
| EPS | ★ 0.96 | 0.20 |
| Revenue | N/A | ★ $605,494,000.00 |
| Revenue This Year | $6.35 | $24.25 |
| Revenue Next Year | $2.29 | $18.75 |
| P/E Ratio | ★ $78.86 | $344.30 |
| Revenue Growth | N/A | ★ 37.13 |
| 52 Week Low | $46.78 | $60.11 |
| 52 Week High | $86.94 | $156.00 |
| Indicator | PHIN | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 42.66 |
| Support Level | $68.81 | $64.90 |
| Resistance Level | $81.04 | $71.14 |
| Average True Range (ATR) | 3.00 | 4.00 |
| MACD | -0.78 | -0.31 |
| Stochastic Oscillator | 14.99 | 25.29 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.